Budget Guide,WARNING LETTER

The FDA warning letter concerning Hims compounded semaglutide in 2025 has brought significant attention to the regulatory landscape of compounded drugs, particularly those marketed for weight loss. This action by the FDA underscores a broader crackdown on telehealth companies making potentially misleading claims about compounded versions of popular medications like semaglutide.

Several warning letters were issued by the FDA in 2025 to numerous telehealth companies, including Hims & Hers. These letters specifically addressed concerns about the marketing of compounded semaglutide and other GLP-1 receptor agonists. The core issue highlighted in these FDA warning letters is that compounded drugs are not FDA-approved. Companies were found to be making claims that implied their compounded products were equivalent to FDA-approved medications, which is a violation of regulatory guidelines. For instance, Hims & Hers was among the entities that received a warning letter for such practices.

The FDA's stance is that while compounded drugs can serve a legitimate purpose when a patient has a specific medical need for a modified medication not available commercially, they must not be marketed as generic alternatives to FDA-approved drugs. The FDA warned that such claims can be false or misleading, potentially leading consumers to believe they are receiving a product with the same safety and efficacy profile as an approved medication. This has led to significant market reactions, with Hims & Hers falls 8% as FDA issues warning letter being a notable example of the financial impact of these regulatory actions.

Specifically regarding semaglutide, the FDA has expressed concerns about the purity and composition of compounded semaglutide products. In April 2025, the agency warned that some compounded semaglutide products might contain salts and impurities, which differ from the approved formulations. This is particularly relevant given that Hims & Hers has withdrawn its $49 compounded semaglutide pill following pressure from health officials. The FDA's actions aim to ensure patient safety and prevent the marketing of unapproved or potentially substandard drug products.

The FDA also issued warning letters to 30 telehealth companies in 2025 as part of this intensified enforcement. These letters are a clear signal of the FDA's intent to regulate the promotion of compounded GLP-1 products more strictly. The agency has emphasized that compounded drugs are not FDA-approved, and claims suggesting otherwise are unacceptable. The FDA's enforcement actions can include sending warning letters, pursuing court injunctions, or conducting inspections.

Industry stakeholders, including Novo Nordisk, the manufacturer of Ozempic and Wegovy (which contain semaglutide), have also voiced concerns about the proliferation of compounded semaglutide. Novo Nordisk has called out the dangers of compounded GLP-1s, highlighting that these products do not undergo the same rigorous testing for safety and efficacy as FDA-approved medications. The PI for Ozempic itself contains a boxed warning regarding the risk of thyroid C-cell tumors, a crucial piece of information for patients and prescribers that may not be adequately communicated for compounded versions.

The regulatory environment surrounding compounded semaglutide is complex. While the FDA's actions focus on marketing and approval processes, there are also underlying issues such as drug shortages that can drive demand for compounded alternatives. The FDA's February 21, 2025 decision to declare an end to the Wegovy shortage, for example, triggered a lawsuit from drug compounders, illustrating the ongoing tension in this market. Ultimately, the series of FDA warning letters and regulatory actions in 2025 serve as a critical reminder that companies marketing compounded semaglutide must adhere to strict guidelines to avoid misleading consumers and ensure patient safety. The FDA continues to monitor these activities, and companies like HIMS must navigate these regulations carefully to avoid further penalties.